Cullinan Q3 net loss $50.6M; focuses on T cell engagers; cash runway into 2029

Cullinan Therapeutics, Inc.

Net loss $50.6M vs $40.6M YoY; R&D expense $42.0M, G&A $13.6M.
Cash & investments $475.5M at Sept 30, 2025; runway expected into 2029.
CLN-049 showed ~30% CRc in R/R AML; oral presentation at ASH 2025.
CLN-978 initial SLE & RA safety/B-cell data expected H1 2026.
Discontinued CLN-619 and CLN-617; partner Taiho plans NDA for zipalertinib by year-end.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.